Short answer
HAEMONETICS CORP (HAE) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 27, 2025. Quarterly revenue was $327M (down 5.3% year over year) with net income of $39M.
Q3 2025 key financials · XBRL
- Revenue
- $327M
- −5.3% YoY · +1.8% QoQ
- Net income
- $39M
- +14.3% YoY · +13.7% QoQ
- Operating margin
- 17.9%
- Gross margin
- 59.5%
- EPS (diluted)
- $0.81
- +22.7% YoY · +15.7% QoQ
Source: XBRL data from the HAEMONETICS CORP (HAE) Q3 2025 10-Q on SEC EDGAR. USD.
HAEMONETICS CORP Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Net revenue $327.3M, down 5.3% YoY from $345.5M
- Operating margin 17.9% vs 15.0% YoY; net margin 11.8% vs 9.8%
- Best segment Hospital revenue $145.5M, up 5.1%; Blood Management Technologies up 13.0%
- Worst segment Blood Center revenue $56.5M, down 17.6%, driven by Whole Blood divestiture
- Cash $296.4M vs $306.8M; operating cash flow $128.7M; $75.0M share repurchase completed
Risk Factors
- No material changes to 10-K risk factors for fiscal year ended March 29, 2025
- Carried-forward risks include regulatory compliance exposure affecting medical-device operations
- Carried-forward operational risks include competition and execution pressures affecting near-term performance
- Carried-forward financial risks include liquidity and debt obligations
- $75.0 million accelerated share repurchase completed in September 2025, leaving $425.0 million authorization
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other HAEMONETICS CORP quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.